New drug offers hope for lymphoma patients who failed CAR T-Cell therapy
NCT ID NCT07453095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial is testing a drug called glofitamab in 41 people with mantle cell lymphoma whose cancer did not respond or came back after CAR T-cell therapy. The goal is to see if glofitamab can shrink or control the cancer. Researchers will measure how many patients achieve a complete response (no cancer detected) during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab
- What this could lead to
- If successful, glofitamab could offer a new treatment option for mantle cell lymphoma patients who have not responded to or relapsed after CAR T-cell therapy.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 41 participants, so results may not apply to all patients. Glofitamab may cause side effects, and it is not expected to cure the disease; ongoing management may still be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia
NOT_YET_RECRUITINGPalermo, Italy
-
A.O.U. Città della Salute e della Scienza - Ematologia Universitaria
NOT_YET_RECRUITINGTorino, Italy
-
AOU SS. Antonio e Biagio e Cesare Arrigo - SCDU Ematologia
NOT_YET_RECRUITINGAlessandria, Italy
-
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
NOT_YET_RECRUITINGMilan, Italy
-
ASST Spedali Civili - Ematologia
NOT_YET_RECRUITINGBrescia, Italy
-
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia
NOT_YET_RECRUITINGFlorence, Italy
-
Azienda Ospedaliera Universitaria Integrata di Verona - U.O. Ematologia
NOT_YET_RECRUITINGVerona, Italy
-
Azienda Ospedaliera Universitaria Pisana - U.O. Ematologia
NOT_YET_RECRUITINGPisa, Italy
-
Grande Ospedale Metropolitano Bianchi Melacrino Morelli - C.T.M.O.
RECRUITINGReggio Calabria, Italy
-
Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia - Ematologia e terapie cellulari
NOT_YET_RECRUITINGGenova, Italy
-
P.O. Spirito Santo di Pescara - UOC Ematologia Dipartimento Oncologico Ematologico - ASL Pescara
NOT_YET_RECRUITINGPescara, Italy
-
Policlinico S.Orsola-Malpighi - Istituto di Ematologia Seragnoli
NOT_YET_RECRUITINGBologna, Italy
-
Policlinico Umberto I - Universitа "La Sapienza" - Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione
NOT_YET_RECRUITINGRoma, Italy
-
ULSS 8 Berica - Ospedale S. Bortolo - Ematologia
NOT_YET_RECRUITINGVicenza, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients